Minneapolis – October 30, 2013CVRx, Inc., a privately held medical device company, has closed on an additional $12 million under its Series F financing. This brings the total raised in the Series F financing to $42 million.

CVRx plans to use the funding for the primary purposes of advancing its clinical trials and expanding its international commercial activities. New investors added in this round of financing included Ysios Capital, DaVita HealthCare Partners Inc. and others. In conjunction with this transaction, Josep Sanfeliu, General Partner of Ysios Capital, joined the CVRx Board of Directors.

“CVRx is recognized as a strong, innovative leader,” said Sanfeliu. “I am excited to join the Board of Directors as a European active medtech investor and look forward to working with the CVRx team to build upon their clinical and commercial success.”

About Ysios and DaVita

Ysios Capital, founded in 2008, is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid stage human healthcare and life science companies. The Ysios Capital team includes experienced professionals with complementary expertise in investing and building healthcare and biotechnology companies. For more information, visit Ysioscapital.com.

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2013, DaVita operated or provided administrative services at 2,010 outpatient dialysis centers located in the United States serving approximately 159,000 patients. The company also operated 48 outpatient dialysis centers located in ten countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, visit DaVita.com.

About CVRx, Inc.

CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis. The company has developed Barostim neo, a novel medical device system designed to treat hypertension and heart failure, two major unmet medical needs. Barostim neoreceived CE marking for the treatment of hypertension in Europe. It is under clinical evaluation for the treatment of heart failure in Europe and the United States and under clinical evaluation for the treatment of hypertension in the United States. CVRx has treated more than 625 patients with its patented devices. For more information, visit Cvrx.com.

Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

La ciencia revela seis ejercicios para n...

by Agencia Sinc

Un nuevo estudio identifica el jogging y otras cinco actividades como ...

Photos Stream